Optibrium Raises Investment to Advance Computer-Aided Drug Discovery
Investment by Kester Capital will drive commercial growth and the development of new products to improve speed, efficiency, and productivity of the discovery process
CAMBRIDGE, UK, 10 February 2021: Optibrium™, a developer of software for drug discovery, today announced it has raised significant investment from Kester Capital, a leading UK mid-market private equity firm typically investing between £10 to £20 million per deal. The funding will accelerate the development of the business through organic growth and acquisition. Currently, more than 150 organisations worldwide deploy Optibrium’s technology in their research programs, including five of the top ten global pharmaceutical companies.
Founded in 2009 by Matt Segall, CEO, and Ed Champness, Chief Scientific Officer, Optibrium is based in Cambridge, UK with offices in the USA in Boston and San Francisco. Optibrium’s products enable preclinical drug discovery, focusing on ‘hit to lead’ and ‘lead optimisation’ phases. Their lead products are StarDrop™ and Cerella™. StarDrop is a comprehensive suite of integrated software for small molecule design, optimisation, and data analysis that enhances the drug discovery process’s speed and productivity. The Cerella™ platform delivers groundbreaking and proven artificial intelligence technology that learns from complex drug discovery data to target high-potential chemical compounds.
The market for computer-aided drug discovery (CADD) is fast-growing, driven by the increasing capabilities and sophistication of software tools that can deliver material cost and time savings for drug developers. Independent market research predicts that the global CADD market will surpass $4.8 billion by 2026, rising from $1.5 billion in 2018 at a CAGR of 15.5%.
Adam Maidment, managing partner of Kester Capital, said:
“Optibrium is a cutting edge software business that is driving some of the most exciting developments within computer-aided drug discovery. We had been tracking the business for some time and were really impressed by the team and the business’ achievements. We are looking forward to working with Matt and Ed to grow the business.”
Matt Segall, CEO of Optibrium, said:
“We are delighted to have Kester Capital on board as an investment partner to continue the successful evolution of the business. Kester has extensive experience in the life sciences sector, and we are looking forward to working with them to capitalise on the substantial market opportunities.”
Notes to Editors:
Email: [email protected]
Phone: +44 (0)7771 730919
Head of Marketing
E-mail: [email protected]
Phone: +44 (0)1223 815903
About Optibrium Ltd
Optibrium provides elegant software that guides successful preclinical drug discovery and its computer-aided drug discovery solutions improve speed, efficiency, and productivity of the discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups. For further information, visit www.optibrium.com.
About Kester Capital
Kester Capital is a primary buyout specialist, led by an entrepreneurial and experienced team and focused on UK businesses that require capital in order to unlock their potential.
This off-market deal is Kester Capital’s third investment in the Life Sciences sector and follows the successful closing of its latest fund, Kester Capital II, which had its final close in August 2020 at £90m. Despite challenging market conditions, the fundraise was oversubscribed and exceeded its target with a diverse group of new and existing institutional investors.
 Computer-Aided Drug Discovery Market (2020), Research Dive market research.